Injectable Nano-Micron AKBA Delivery Platform for Treatment of Tendinopathy in a Rat Model

IF 3.9 3区医学 Q2 ENGINEERING, BIOMEDICAL Journal of biomedical materials research. Part A Pub Date : 2024-12-13 DOI:10.1002/jbm.a.37844

Qibin Han, Yinhua Qian, Lang Bai, Jing Zhou, Yuefeng Hao, Dan Hu, Zhouzhou Zhang, Xing Yang

{"title":"Injectable Nano-Micron AKBA Delivery Platform for Treatment of Tendinopathy in a Rat Model","authors":"Qibin Han, Yinhua Qian, Lang Bai, Jing Zhou, Yuefeng Hao, Dan Hu, Zhouzhou Zhang, Xing Yang","doi":"10.1002/jbm.a.37844","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Tendinopathy is a disorder characterized by pain and reduced function due to a series of changes in injured or diseased tendons. Inflammation and collagen degeneration are key contributors to the onset and chronic nature of tendinopathy. Acetyl-11-keto-β-boswellic acid (AKBA) is an effective anti-inflammatory agent widely used in chronic inflammatory disorders and holds potential for tendinopathy treatment; however, its therapeutic efficacy is limited by poor aqueous solubility. Here, we fabricated AKBA-encapsulated cationic liposome-gelatin methacrylamide (GelMA) microspheres (GM-Lipo-AKBA) using thin-film hydration and microfluidic technology for drug delivery therapy. GM-Lipo-AKBA exhibited high encapsulation efficiency, extended AKBA release for over 4 weeks, and prolonged degradation. In vitro and in vivo experiments demonstrated its effectiveness in improving inflammation and ECM remodeling in tendinopathy. In summary, the injectable nano-micron drug delivery platform provides a promising strategy for the sustained and localized delivery of AKBA for tendinopathy treatment.</p>\n </div>","PeriodicalId":15142,"journal":{"name":"Journal of biomedical materials research. Part A","volume":"113 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical materials research. Part A","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jbm.a.37844","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Tendinopathy is a disorder characterized by pain and reduced function due to a series of changes in injured or diseased tendons. Inflammation and collagen degeneration are key contributors to the onset and chronic nature of tendinopathy. Acetyl-11-keto-β-boswellic acid (AKBA) is an effective anti-inflammatory agent widely used in chronic inflammatory disorders and holds potential for tendinopathy treatment; however, its therapeutic efficacy is limited by poor aqueous solubility. Here, we fabricated AKBA-encapsulated cationic liposome-gelatin methacrylamide (GelMA) microspheres (GM-Lipo-AKBA) using thin-film hydration and microfluidic technology for drug delivery therapy. GM-Lipo-AKBA exhibited high encapsulation efficiency, extended AKBA release for over 4 weeks, and prolonged degradation. In vitro and in vivo experiments demonstrated its effectiveness in improving inflammation and ECM remodeling in tendinopathy. In summary, the injectable nano-micron drug delivery platform provides a promising strategy for the sustained and localized delivery of AKBA for tendinopathy treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肌腱病是一种因受伤或患病肌腱发生一系列变化而导致疼痛和功能减退的疾病。炎症和胶原蛋白变性是导致肌腱病发病和慢性化的主要原因。乙酰基-11-酮-β-乳香酸（AKBA）是一种有效的抗炎药物，被广泛用于慢性炎症性疾病的治疗，并具有治疗肌腱病的潜力；然而，由于其水溶性较差，其疗效受到了限制。在此，我们利用薄膜水合和微流控技术制备了阳离子脂质体-明胶甲基丙烯酰胺（Gelatin methacrylamide，GelMA）包封微球（GM-Lipo-AKBA），用于给药治疗。GM-Lipo-AKBA 具有封装效率高、AKBA 释放时间长达 4 周以上、降解时间长等特点。体外和体内实验证明，它能有效改善肌腱病的炎症和 ECM 重塑。总之，这种可注射的纳米微米给药平台为 AKBA 持续、局部给药治疗肌腱病提供了一种前景广阔的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of biomedical materials research. Part A 工程技术-材料科学：生物材料

CiteScore

10.40

自引率

2.00%

发文量

135

审稿时长

3.6 months

期刊介绍： The Journal of Biomedical Materials Research Part A is an international, interdisciplinary, English-language publication of original contributions concerning studies of the preparation, performance, and evaluation of biomaterials; the chemical, physical, toxicological, and mechanical behavior of materials in physiological environments; and the response of blood and tissues to biomaterials. The Journal publishes peer-reviewed articles on all relevant biomaterial topics including the science and technology of alloys,polymers, ceramics, and reprocessed animal and human tissues in surgery,dentistry, artificial organs, and other medical devices. The Journal also publishes articles in interdisciplinary areas such as tissue engineering and controlled release technology where biomaterials play a significant role in the performance of the medical device. The Journal of Biomedical Materials Research is the official journal of the Society for Biomaterials (USA), the Japanese Society for Biomaterials, the Australasian Society for Biomaterials, and the Korean Society for Biomaterials. Articles are welcomed from all scientists. Membership in the Society for Biomaterials is not a prerequisite for submission.